Quantitative method for Hex4, lyso-GM1, Fuc-GlcNAc-Asn, and lyso-sulfatide in cerebrospinal fluid

JP7874706B2Active Publication Date: 2026-06-16JCR PHARMACEUTICALS CO LTD

Patent Information

Authority / Receiving Office
JP · JP
Patent Type
Patents
Current Assignee / Owner
JCR PHARMACEUTICALS CO LTD
Filing Date
2024-12-04
Publication Date
2026-06-16

Smart Images

  • Figure 0007874706000085
    Figure 0007874706000085
  • Figure 0007874706000086
    Figure 0007874706000086
  • Figure 0007874706000087
    Figure 0007874706000087
Patent Text Reader

Abstract

To provide a method for determining a quantity of lyso-sulfatide in a brain.SOLUTION: A method for determining a quantity of lyso-sulfatide in cerebrospinal fluid includes the steps of: adding an inner standard material to a solution including the cerebrospinal fluid; obtaining an eluate by performing liquid chromatography on the solution containing the cerebrospinal fluid to which the internal standard material was added; and performing mass analysis on the eluate. The cerebrospinal fluid is obtained from a patient who stores lyso-sulfatide and / or sulfatide in the body.SELECTED DRAWING: Figure 39
Need to check novelty before this filing date? Find Prior Art

Claims

1. A method for quantifying lyso-sulfatide contained in cerebrospinal fluid, The steps include adding an internal standard substance to a solution containing cerebrospinal fluid, The steps include: obtaining an eluate by subjecting a solution containing cerebrospinal fluid to which the internal standard substance has been added to liquid chromatography; The step of subjecting the eluate to mass spectrometry, It consists of, A method wherein the internal standard is represented by the following formula [X]. 【Chemistry 10】

2. The method according to claim 1, wherein the liquid chromatography is reversed-phase chromatography.

3. The method according to claim 1 or 2, wherein the lyso-sulfatide is measured in comparison with an internal standard.

4. The method according to any one of claims 1 to 3, wherein the cerebrospinal fluid is obtained from a patient with a disease in which lyso-sulfatide and / or sulfatide accumulates in the body.

5. The method according to claim 4, wherein the disease is metachromatic leukodystrophy.

6. The method according to claim 4 or 5, wherein the patient has received treatment to reduce the amount of lyso-sulfatide and / or sulfatide present in the body.